American Peptide to expand manufacturing capacity at Vista
Move will enable APC to process large-scale peptide production and meet cGMP standards
The expansion of its facility in Vista, California, US will allow APC to process large-scale peptide production needs while still meeting the high standards of GMP regulations.
The expansion will take place in three main areas of purification, synthesis and lyophilisation.
Four new peptide purification suites will be added for large-scale purification projects. The company also plans to build two new synthesis suites, both for solution phase and solid phase.
For the lyophilisation process, another capacity tray will be added to allow the release of multi-kg single batches of peptide APIs.
‘As the demand for peptide-based therapies increases, we are constantly seeking ways to enhance our operations to meet customer demands for large volumes without compromising our high standards for production,’ said Takahiro Ogata, chief operating officer of APC.
In addition to the expansion of its manufacturing capabilities, APC continues to offer the Total Peptide Management programme as a way of providing customers with increased regulatory support and value-added services. The programme offers a broad portfolio of peptides, and expert consultation to support customers as drug products move from discovery to development and commercialisation.
You may also like
Trending Articles
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Ingredients
![CPPs: beating drug delivery barriers]()
CPPs: beating drug delivery barriers
Cell-penetrating peptides are a promising tool for cellular import of drug cargos and have been applied in the delivery of a variety of therapeutic molecules. Jyothi Thundimadathil and Archana Gangakhedkar, American Peptide Co, highlight recent application studies
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Ingredients
![Bicyclic peptides for a new class of targeted drugs]()
Bicyclic peptides for a new class of targeted drugs
Bicyclic peptides are an emerging class of molecules used to explore new cellular sites not treatable using small molecules or large antibodies. Archana Gangakhedkar, American Peptide Company, reveals some of the properties that offer a new route to targeting diseases
Manufacturing
![SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs]()
SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs
Featuring the well-known EVERIC® lyo coating, EVERIC® lyo & amber is designed for lyophilised, light-sensitive antibody-drug-conjugates (ADCs). It offers reliable light protection at the primary packaging level, already during the fill-and-finish process. EVERIC amber is the first specialty vial for highly light-sensitive medications that simultaneously meets regulatory light transmission requirements in the EU, the U.S., and Japan
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![Portable gas detection in the pharmaceutical sector]()
Portable gas detection in the pharmaceutical sector
Gas safety is a critical consideration in the pharmaceutical sector. Hazardous gases and airborne contaminants are common by-products of manufacturing processes … and employers must control worker exposure in accordance with relevant legislation and industry standards
Manufacturing
![New legal duties for QPs in decentralised manufacturing]()
New legal duties for QPs in decentralised manufacturing
In this clip, Dr. Peter Gough explains that QPs will be responsible for supervising decentralised activities, conducting regular audits, carrying out periodic on-site visits, confirming GMP compliance to regulatory authorities and notifying changes that may affect quality or safety